<DOC>
	<DOCNO>NCT02115503</DOCNO>
	<brief_summary>The purpose treatment registry study determine monthly infusion Intravenous Immunoglobulin ( IVIg ) 6 month neutralize donor specific antibody think responsible chronic rejection episodes renal transplant subject . 162 renal transplant subject receive IVIg 5 % 2gm/kg/month 6 month follow 3 year .</brief_summary>
	<brief_title>A Prospective , Global , Multi-center , Treatment Registry Study Intravenous Immunoglobulin Maintenance Therapy Alloantibody Positive Renal Allograft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Isoantibodies</mesh_term>
	<criteria>Subject 18 year age older Able provide voluntary write informed consent Renal transplant recipient least 1 month posttransplant On stable dos maintenance immunosuppression least 14 day prior study entry remain stable maintenance dos duration study Presence DSA great equal 1000 mean fluorescence intensity ( MFI ) single antigen bead assay via Luminex ( normalized 2,000 15,000 MFI , inclusive ) measure within 6 month prior consent Female subject must postmenopausal least 1 year , surgically sterilize , must agree use two effective method birth control time consent 30 day last dose IVIg . Male subject must surgically sterilize , must agree use two effective method birth control time consent 30 day last dose IVIg Subject compliant intend available followup study period 3 year Multiorgan transplant History anaphylactic severe systemic reaction human immunoglobulin IgA deficient subject antibodies IgA history hypersensitivity Serum creatinine &gt; 3.0 mg/dL within 90 day prior consent Recipients ABO incompatible kidney transplant Acute rejection within 180 day ( 6 month ) prior consent define : 1 . Biopsy proven acute Cellular Rejection [ Banff grade I ( include IA IB ) , grade II ( include IIA IIB ) grade III ] ; 2. antibodymediated rejection C4d positivity , 3. chronic rejection C4d positivity ( C4d positivity define stain diffuse peritubular capillary area . Isolated C4d glomerular stain C4d stain &lt; 50 % peritubular capillary exclusion criterion ) . Borderline cellular rejection exclude ( Banff 2005 ) , 4 . Clinical sign symptom acute rejection include elevated creatinine , fever 100 degree , pain tenderness around transplanted kidney , fluid retention hand , leg , foot , ankle eyelid , sudden weight gain ( 24 pound day , 5 pound week ) , decrease urine output amount fluid intake , dark yellow orange urine output , flulike symptom , chill , ache , tiredness , dizziness , nausea , loss appetite , weakness , fatigue , vomit general sense feeling well ( Note : NOT sign symptom need present document acute rejection ) Evidence proteinuria ( &gt; 3 gram ) within 90 day ( 3 month ) prior consent Active CMV+ EBV+ viremia require , require , antiviral therapy History HCV , HIV and/or HBsAg positivity History posttransplant lymphoproliferative disease . Active BK/polyomavirus nephropathy , BK/polyomavirus nephritis require , require , antiviral therapy ( prophylactic ) Recipients kidney donor test positive HIV , HBsAg antiHCV . History malignancy within past 5 year consider cure , exception complete resection localize basal cell carcinoma skin ( excise â‰¥ 1 year prior enrollment ) . Subjects receive everolimus , sirolimus azathioprine immunosuppressive agent unwilling , unable , change mycophenolate mofetil mycophenolic acid within 14 day prior consent White blood cell count &lt; 1,000/mm3 within 90 day prior consent Platelet count &lt; 60,000/mm3 within 90 day prior consent Evidence severe liver disease abnormal liver profile ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 3 time upper limit normal [ ULN ] ) within 90 day prior consent Total bilirubin &gt; 1.5 time ULN within 90 day prior consent Posttransplant history cardiovascular disease within 180 day ( 6 month ) prior consent define : 1 . Electrocardiographic evidence MI , 2 . Electrocardiographic evidence acute ischemia , 3 . Electrocardiographic evidence severe conduction system abnormalities OR 4 . New York Heart Association ( NYHA ) Class II IV heart failure ( Subjects cardiac abnormality may include documented investigator clinically significant ) Pregnant nursing ( lactate ) woman Enrolled treatment study within 30 day consent Serious medical illness ( renal disease ) , psychiatric illness likely interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>